XOMA News and Press, XOMA Corporation

2024-07-19 08:30:00 ET Summary Royalty interests present a lucrative opportunity for passive income from the popularity and demand for certain goods. Get paid on autopilot via public companies that manage a portfolio of royalty interests and distribute the proceeds to shareholders...

2024-07-05 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-29 02:31:45 ET Summary XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs. XOMA’s diverse IP portfolio spans various therapeutic areas, including oncology, immu...

EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Revie...

2024-06-04 07:06:40 ET More on ImmunityBio, LadRx, etc. ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gains ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications ImmunityBio Lights Up: Anktiva's FDA Nod Sha...

2024-06-04 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-25 06:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2 nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in ...

2024-05-09 07:53:40 ET More on XOMA Day One wins FDA nod for brain cancer therapy, Ojemda Xoma to acquire Kinnate Biopharma for $2.3352 - $2.5879 per share Seeking Alpha’s Quant Rating on XOMA Historical earnings data for XOMA Financial informa...

Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in...